Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA1092481
Max Phase: Preclinical
Molecular Formula: C23H38ClN3O
Molecular Weight: 371.57
Molecule Type: Small molecule
Associated Items:
ID: ALA1092481
Max Phase: Preclinical
Molecular Formula: C23H38ClN3O
Molecular Weight: 371.57
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCCCCCCCCCCCc1ccc(C(=O)NC2(C(=N)N)CC2)cc1.Cl
Standard InChI: InChI=1S/C23H37N3O.ClH/c1-2-3-4-5-6-7-8-9-10-11-12-19-13-15-20(16-14-19)21(27)26-23(17-18-23)22(24)25;/h13-16H,2-12,17-18H2,1H3,(H3,24,25)(H,26,27);1H
Standard InChI Key: APHADGNZJGOQKN-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 371.57 | Molecular Weight (Monoisotopic): 371.2937 | AlogP: 5.35 | #Rotatable Bonds: 14 |
Polar Surface Area: 78.97 | Molecular Species: BASE | HBA: 2 | HBD: 3 |
#RO5 Violations: 1 | HBA (Lipinski): 4 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: | CX Basic pKa: 11.11 | CX LogP: 5.89 | CX LogD: 3.49 |
Aromatic Rings: 1 | Heavy Atoms: 27 | QED Weighted: 0.23 | Np Likeness Score: -0.20 |
1. Mathews TP, Kennedy AJ, Kharel Y, Kennedy PC, Nicoara O, Sunkara M, Morris AJ, Wamhoff BR, Lynch KR, Macdonald TL.. (2010) Discovery, biological evaluation, and structure-activity relationship of amidine based sphingosine kinase inhibitors., 53 (7): [PMID:20205392] [10.1021/jm901860h] |
2. Kennedy AJ, Mathews TP, Kharel Y, Field SD, Moyer ML, East JE, Houck JD, Lynch KR, Macdonald TL.. (2011) Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells., 54 (10): [PMID:21495716] [10.1021/jm2001053] |
3. Gustin DJ, Li Y, Brown ML, Min X, Schmitt MJ, Wanska M, Wang X, Connors R, Johnstone S, Cardozo M, Cheng AC, Jeffries S, Franks B, Li S, Shen S, Wong M, Wesche H, Xu G, Carlson TJ, Plant M, Morgenstern K, Rex K, Schmitt J, Coxon A, Walker N, Kayser F, Wang Z.. (2013) Structure guided design of a series of sphingosine kinase (SphK) inhibitors., 23 (16): [PMID:23845219] [10.1016/j.bmcl.2013.06.030] |
Source(1):